MYGN: Myriad Genetics Company Total Revenue

Myriad Genetics - graphic logo of issuer MYGN

The growth of Myriad Genetics, Inc. (MYGN) relies on the integration of genetic screenings into insurance packages while maintaining strict control over legal costs. Business efficiency is driven by Medicare reimbursement and the average order value of MyRisk tests. Revenue is based on high-tech diagnostics in oncology and the reproductive sphere. The company's sales volume reflects demand dynamics, and the value of 0.80 captures this metric.

Myriad Genetics, Inc. (MYGN) Revenue and Sales Volume: for the period 07/04/2022 - 11/16/2026

Analytical breakdowns for Myriad Genetics, Inc.

- stock quotes and analyst forecast:
General company analysis:MYGN (myriad.com)
Manufactured product of Myriad Genetics Corp

Myriad Genetics, Inc. (MYGN) sales represent the aggregate daily cash flow from the realization of genetic tests. Investors utilize this dynamic volume to assess liquidity and identify the asset's fundamental bottom. By analyzing the company's sales history, one can uncover hidden revenue trends. This metric is critical for Myriad Genetics, Inc. (MYGN) due to its dependence on insurance reimbursements. The stability of this flow confirms the business's resilience against patent disputes and R&D expenditures.